Scarica l'app Stockscreener
5.97
6.23%
0.35
Dopo l'orario di chiusura:
6.00
0.03
+0.50%
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
Seres Therapeutics (MCRB) Faces Sharp Decline, Tests Key Support LevelsETH Profile - newsline.com
We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate - Yahoo Finance
Seres Therapeutics (MCRB) Slips 2.62% as Shares Test Key Support at $6.00Bull Pennant - newsline.com
Cambridge biotech surrenders half its lab space amid cash crunch - The Business Journals
MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits
Seres Therapeutics (MCRB) Secures Cash Runway Extension Through Key Transactions - GuruFocus
Seres Therapeutics Secures $25M from Nestlé, Restructures Lease to Extend Cash Runway Into 2027 - Minichart
Seres Therapeutics secures $25M from Nestlé Health Science By Investing.com - Investing.com South Africa
Seres Therapeutics Reshapes Finances with Lease Restructuring - TipRanks
Seres Therapeutics Extends Cash Runway to 2027 Through Financial Restructuring and Lease Adjustments - geneonline.com
Seres Therapeutics Secures $25 Million from Nestlé Health Science and Reduces Facility Costs to Enhance Financial Position - Quiver Quantitative
Seres Therapeutics Announces Two Transactions To Strengthen Balance Sheet, Reduce On-Going Lease Costs And Extend Projected Operating Cash Runway Well Into The First Quarter Of 2027 - TradingView
Seres Therapeutics secures $25M from Nestlé Health Science - Investing.com
Seres Therapeutics (Nasdaq: MCRB) extends cash runway into 2027 - Stock Titan
Drugmaker Seres gets $25M from Nestlé, cuts Boston-area lab lease costs - Stock Titan
Seres Therapeutics, Inc. Files 8-K Current Report with SEC Detailing Corporate Information (May 30, 2026) - Minichart
[8-K] Seres Therapeutics, Inc. Reports Material Event - Stock Titan
Seres Therapeutics (MCRB) Slips 3.4%, Testing Key Support at $6.95Range Breakout - newsline.com
Seres Therapeutics (MCRB) Declines 2.18% as Stock Approaches Key SupportHigh Reward Trades - newsline.com
MCRB News | SERES THERAPEUTICS INC (NASDAQ:MCRB) - ChartMill
Seres Therapeutics (MCRB) Edges Higher Amid Steady Support and Resistance DynamicsDark Pool Volume - The Legal Advocate
Seres Therapeutics (MCRB) Declines 5.93% as Selling Pressure IntensifiesLow Risk Entry Stocks - The Legal Advocate
MCRB Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues R&D FocusEarnings Beat Streak - The Legal Advocate
MCRB SEC FilingsSeres Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Seres Therapeutics (MCRB) Q1 2026 Miss: What Went WrongEPS Surprise History - Newser
Seres Therapeutics (MCRB) Q1 2026 Miss: Should Investors Be Worried?EPS Estimate Trend - The Legal Advocate
MCRB: AI-driven microbiome therapeutics pipeline advances toward key clinical and commercial milestones - TradingView
Teresa L. Young sells shares; MCRB (NASDAQ: MCRB) files Form 144 notice - Stock Titan
Officer at Seres Therapeutics (NASDAQ: MCRB) sells 79 shares under 10b5-1 tax plan - Stock Titan
Seres Therapeutics (MCRB) officer sells shares after RSU vesting under 10b5-1 plan - Stock Titan
Microbiome Therapeutics Market Size, Share | Forecast [2034] - Fortune Business Insights
Seres Therapeutics stock (US81750R1023): Q1 2026 results and private placement - AD HOC NEWS
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference - The Manila Times
How to watch Seres Therapeutics’ BioConnect investor presentation - Stock Titan
How Seres Therapeutics (MCRB) balances short term and long term focus | Q1 2026: EPS Misses ViewsNCAV - Newser
MSN Money - MSN
The working capital efficiency at Seres Therapeutics (MCRB) | Q1 2026: EPS Misses EstimatesProfit Margin - newser.com
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Seres Therapeutics 1Q 2026: Revenue $358K, EPS $(2.08) — 10-Q Summary - TradingView
Seres Therapeutics (NASDAQ: MCRB) Q1 2026 loss and going-concern risk - Stock Titan
Seres Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics (Nasdaq: MCRB) Q1 2026 results and cash runway - Stock Titan
Seres awaits SER-155 data in weeks with cash through Q3 - Stock Titan
Seres presents preclinical data on IBD drug candidate SER-603 - Investing.com UK
Seres presents preclinical data on IBD drug candidate SER-603 By Investing.com - Investing.com South Africa
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease - The Manila Times
Experimental IBD microbiome therapy earns DDW poster honor - Stock Titan
Seres Therapeutics Presents Preclinical Data at Digestive - GlobeNewswire
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):